# US 2010/0074903 A1 · Novel antibody formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074903 A1
- Document ID: US20100074903A1
- Status: Published application
- Kind: A1
- Application number: 12/559,555
- Filed: 2009-09-15
- Published: 2010-03-25
- Earliest claimed: 2008-09-19
- Inventors: Ulla Grauschopf; Hanns-Christian Mahler; Oliver Boris Stauch
- Web page: https://patentgrep.com/patent/US20100074903A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 11/06: Antiasthmatics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/18: against material from animals or humans
- C07K 16/2854: {against selectins, e.g. CD62}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.

## Claims

### Claim 1

A pharmaceutical formulation having a pH in the range of 4.0 to 7.0 comprising:
1 to 200 mg/mL of an antibody against P-selectin;
1 to 100 mM of a buffer;
0.001 to 1% of a surfactant; and
a component selected from the group consisting of:
(a) 10 to 500 mM of a stabilizer;
(b) 10 to 500 mM of a stabilizer and 5 to 500 mM of a tonicity agent; and
(c) 5 to 500 mM of a tonicity agent.

### Claim 2 (depends on 1)

A formulation according to claim 1 which is a liquid formulation or a lyophilized formulation or a liquid formulation reconstituted from a lyophilized formulation.

### Claim 3 (depends on 1)

A formulation according to claim 1, wherein the antibody concentration is in the range of 10 mg/mL to 150 mg/ml.

### Claim 4 (depends on 1)

A formulation according to claim 1, wherein the stabilizer is trehalose.

### Claim 5 (depends on 1)

A formulation according to claim 1, wherein the surfactant is polysorbate.

### Claim 6 (depends on 1)

A formulation according to claim 1, wherein the buffer is a histidine-buffer.

### Claim 7 (depends on 1)

A formulation according to claim 1, which comprises a tonicity agent.

### Claim 8 (depends on 1)

A formulation according to claim 1, wherein the tonicity agent is trehalose.

### Claim 9 (depends on 1)

A formulation according to claim 1, selected from the group consisting of:
(1) a formulation having a pH of about 6.0 comprising 1 to 50 mg/mL huMAb-P-selectin, about 20 mM L-histidine HCl, about 240 mM trehalose, and about 0.02% polysorbate 20;
(2) a formulation having a pH of about 5.2 comprising 1 to 50 mg/mL huMAb-P-selectin, about 20 mM sodium acetate, about 140 mM trehalose, about 75 mM glycine, and about 0.04% polysorbate 20;
(3) a formulation having a pH of about 6.0 comprising 1 to 50 mg/mL huMAb-P-selectin, about 20 mM L-histidine HCl, about 240 mM trehalose, and about 0.02% polysorbate 20; and
(4) a formulation having a pH of about 6.0 comprising 1 to 50 mg/mL huMAb-P-selectin, about 20 mM succinate, about 240 mM trehalose, about 20 mM arginine, and about 0.02% polysorbate 20.
